@article{0a66efc4a0f54420a67fad1401c3920e,
title = "YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma",
abstract = "Head-and-neck squamous cell carcinoma (HNSCC) is the sixth most common group of cancers in the world, and patients have a poor prognosis. Here, we present data indicating that YAP1 may be a strong driver of the onset and progression of oral SCC (OSCC), a major subtype of HNSCC. Mice with tongue-specific deletion of Mob1a/b and thus endogenous YAP1 hyperactivation underwent surprisingly rapid and highly reproducible tumorigenesis, developing tongue carcinoma in situ within 2 weeks and invasive SCC within 4 weeks. In humans, precancerous tongue dysplasia displays YAP1 activation correlating with reduced patient survival. Combinations of molecules mutated in OSCC may increase and sustain YAP1 activation to the point of oncogenicity. Strikingly, siRNA or pharmacological inhibition of YAP1 blocks murine OSCC onset in vitro and in vivo. Our work justifies targeting YAP1 as therapy for OSCC and perhaps HNSCC, and our mouse model represents a powerful tool for evaluating these agents.",
author = "Hirofumi Omori and Miki Nishio and Muneyuki Masuda and Yosuke Miyachi and Fumihito Ueda and Takafumi Nakano and Kuniaki Sato and Koshi Mimori and Kenichi Taguchi and Hiroki Hikasa and Hiroshi Nishina and Hironori Tashiro and Tohru Kiyono and Mak, {Tak Wah} and Kazuwa Nakao and Takashi Nakagawa and Tomohiko Maehama and Akira Suzuki",
note = "Funding Information: We thank H. Togashi, Y. Shimono, and K. Okada (all of Kobe University) for expert technical assistance and critical discussions. We thank J. Wrana (Lunenfeld-Tanenbaum Research Institute) for Tazflox/flox mice and J. S. Gutkind (University of California) for WSU-HN30 cells. We are grateful for the funding provided by the Japanese Society for the Promotion of Science (JSPS; grants 17H01400, 26114005, and 26640081 to A.S.); the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; Nanken-Kyoten, Tokyo Medical and Dental University (TMDU); the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT; grant 11088019 to A.S.); the Japanese Agency for Medical Research and Development [P-CREATE (AMED); grant JP19cm0106114 to A.S.]; the Uehara Memorial Foundation (to A.S.); the Shinnihon Advanced Medical Research Foundation (to A.S.); the Daiichi-Sankyo Scholarship Donation Program (to A.S.). Publisher Copyright: Copyright {\textcopyright} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).",
year = "2020",
doi = "10.1126/sciadv.aay3324",
language = "English",
volume = "6",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "12",
}
